January 2027 may feel several months away, but covered entities should not wait to evaluate the potential impact of HRSA’s revised 340B Rebate Model Pilot Program.
Under the pilot, qualifying manufacturers can apply to provide the 340B ceiling price through a rebate for certain drugs rather than through the traditional upfront discount. Approved plans are expected to take effect January 1, 2027.
For covered entities, readiness starts with understanding how that change could affect day-to-day operations. Read more >



